Suppr超能文献

系统性硬化症相关性与特发性肺动脉高压之间的病理差异。

Pathologic differences between systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.

作者信息

Friedman Samuel H, Harley Russell A, Williams Jacob, Forcucci Jessica A, Ramakrishnan Viswanathan, Strange Charlie, Silver Richard M, Feghali-Bostwick Carol, Argula Rahul G

机构信息

Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.

Department of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.

出版信息

J Scleroderma Relat Disord. 2024 Nov 27:23971983241296721. doi: 10.1177/23971983241296721.

Abstract

Advances in pulmonary arterial hypertension therapies have led to improvements in the quality of life and survival for patients with idiopathic pulmonary arterial hypertension, but these trends have not uniformly translated to patients with systemic sclerosis-associated pulmonary arterial hypertension. In order to better understand the heterogeneity in treatment response and survival, we aimed to examine the histological and immunophenotypic differences between the systemic sclerosis-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension pulmonary vasculopathies. We performed a semi-quantitative lung morphometry-based analysis comparing sections obtained from systemic sclerosis-associated pulmonary arterial hypertension (n = 24), idiopathic pulmonary arterial hypertension (n = 9), and control (n = 13) bio-banked lung tissue specimens. H&E (Hematoxylin and Eosin) and VVG (Verhoeff-Van Gieson)-stained lung sections were analyzed for interstitial and vascular pathology. Immunohistochemistry was used to stain for an array of inflammatory and fibrosis mediators. Baseline demographic and hemodynamic data for each patient were collected via chart review at the time of lung explantation. Plexiform lesions were present in 5/9 (55%) of idiopathic pulmonary arterial hypertension samples, but absent in all systemic sclerosis-associated pulmonary arterial hypertension samples (0/24). Systemic sclerosis-associated pulmonary arterial hypertension lungs demonstrated significantly worse interstitial fibrosis (p = 0.0001) and interstitial cellularity (p = 0.0002) compared to idiopathic pulmonary arterial hypertension lungs. The degree of smooth muscle hypertrophy and pulmonary artery intimal proliferation were not different between systemic sclerosis-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension lungs. Immunohistochemistry analysis revealed that systemic sclerosis-associated pulmonary arterial hypertension lungs exhibited increased interstitial infiltration of CD3 T-cells (p = 0.009), CD20 B-cells (p = 0.01), and CD163 macrophages (p = 0.048) when compared to idiopathic pulmonary arterial hypertension and control lungs. Systemic sclerosis-associated pulmonary arterial hypertension lungs display a distinct pulmonary vascular pathology as well as significant interstitial fibrosis when compared to idiopathic pulmonary arterial hypertension lungs.

摘要

肺动脉高压治疗的进展已使特发性肺动脉高压患者的生活质量和生存率得到改善,但这些趋势并未一致地转化到系统性硬化症相关肺动脉高压患者身上。为了更好地理解治疗反应和生存的异质性,我们旨在研究系统性硬化症相关肺动脉高压与特发性肺动脉高压肺血管病变之间的组织学和免疫表型差异。我们进行了一项基于半定量肺形态学的分析,比较了取自系统性硬化症相关肺动脉高压(n = 24)、特发性肺动脉高压(n = 9)和对照(n = 13)的生物样本库肺组织标本的切片。对苏木精和伊红(H&E)染色以及韦尔霍夫-范吉森(VVG)染色的肺切片进行间质和血管病理学分析。免疫组织化学用于对一系列炎症和纤维化介质进行染色。通过在肺移植时查阅病历收集每位患者的基线人口统计学和血流动力学数据。丛状病变在5/9(55%)的特发性肺动脉高压样本中存在,但在所有系统性硬化症相关肺动脉高压样本中均不存在(0/24)。与特发性肺动脉高压肺相比,系统性硬化症相关肺动脉高压肺表现出明显更严重的间质纤维化(p = 0.0001)和间质细胞增多(p = 0.0002)。系统性硬化症相关肺动脉高压肺与特发性肺动脉高压肺之间的平滑肌肥大程度和肺动脉内膜增殖程度没有差异。免疫组织化学分析显示,与特发性肺动脉高压肺和对照肺相比,系统性硬化症相关肺动脉高压肺表现出CD3 T细胞(p = 0.009)、CD20 B细胞(p = 0.01)和CD163巨噬细胞(p = 0.048)的间质浸润增加。与特发性肺动脉高压肺相比,系统性硬化症相关肺动脉高压肺表现出独特的肺血管病理学以及明显的间质纤维化。

相似文献

8
Pulmonary hypertension in systemic sclerosis.系统性硬化症相关肺动脉高压。
Semin Arthritis Rheum. 2011 Aug;41(1):19-37. doi: 10.1016/j.semarthrit.2010.08.004. Epub 2010 Nov 2.

本文引用的文献

1
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.索他洛尔治疗肺动脉高压的3期试验
N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.
2
Pulmonary Arterial Hypertension.肺动脉高压
N Engl J Med. 2021 Dec 16;385(25):2361-2376. doi: 10.1056/NEJMra2000348.
4
Pulmonary hypertension phenotypes in patients with systemic sclerosis.系统性硬皮病患者的肺动脉高压表型。
Eur Respir Rev. 2021 Aug 17;30(161). doi: 10.1183/16000617.0053-2021. Print 2021 Sep 30.
5
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.索他拉特塞治疗肺动脉高压。
N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277.
7
Systemic sclerosis-associated interstitial lung disease.系统性硬皮病相关性间质性肺疾病。
Lancet Respir Med. 2020 Mar;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1. Epub 2020 Feb 27.
9
The immunopathogenesis of fibrosis in systemic sclerosis.系统性硬化症中纤维化的免疫发病机制。
Clin Exp Immunol. 2019 Mar;195(3):310-321. doi: 10.1111/cei.13238. Epub 2018 Dec 10.
10
Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.细胞外基质在肺动脉高压发病机制中的作用。
Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1322-H1331. doi: 10.1152/ajpheart.00136.2018. Epub 2018 Aug 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验